Posts Tagged ‘academic detailing’

Less pain, more gain: defining an alternative to harmful Medicaid cuts

Monday, February 28th, 2011

(please note most links below are pdfs)

On Friday, Community Catalyst sent a letter to Secretary Sebelius, outlining eight policies states could implement to cut Medicaid costs. We were inspired to weigh in by a series of letters between the Secretary and Republican Governors that contrasted two very different approaches to reducing Medicaid expenditures.

Cutting Coverage vs. Cutting Waste
Republican Governors wrote a letter to Congress and the Administration in January, asking them to lift the Maintenance of Effort (MOE) requirement – the provision in the Affordable Care Act (ACA) that prevents most states from reducing Medicaid eligibility between now and 2014. The basic premise of their letter was that states need to cut low-income children, parents, seniors, and/or people with disabilities off coverage in order to “responsibly manage [their] state budgets.” We anticipate Republican Governors will reiterate this argument at the Energy and Commerce hearing Tuesday about the impact of the ACA on Medicaid.

Secretary Sebelius responded with a letter explaining why that basic premise simply isn’t true (see our blog and summary of her letter.) She outlined dozens of ways states can trim costs in their Medicaid programs without eliminating coverage for vulnerable families. By tackling the inefficiencies in our fragmented health care delivery system, many of the policies she suggested not only cut costs but they also have the potential to improve care for beneficiaries in the process. Sebelius also made it clear that her department remains open to suggestions of additional policies states can pursue to accomplish those dual goals.

When Secretary Sebelius Calls, We Answer
We took the Secretary up on that challenge. Our letter to the Secretary highlights eight additional policies states can pursue to lower Medicaid costs and maintain or improve care. More details about these options can be found in the text of our letter, but here are the highlights:

  • Recalibrate provider payment rates, shifting dollars from inpatient care to outpatient care, to give providers an incentive to treat patients in the lowest-cost settings.
  • Rebalance long-term care dollars away from institutions and towards home- and community-based settings by taking advantage of more funding opportunities created by the ACA to help states front the cost of this readjustment.
  • Better integrate care for those who are eligible for both Medicaid and Medicare by expanding existing programs such as the Program for All-Inclusive Care for the Elderly (PACE) and fully-integrated Special Needs Plans (SNPs) that provide a comprehensive and patient-centered model of care.
  • Reduce preventable hospital readmissions and complications by tying hospitals’ payment levels to their preventable complication and readmission rates.
  • Increase the use of generic drugs by making it easier for pharmacists to substitute equivalent generics when the patient was prescribed a brand name drug.
  • Improve evidence-based drug selection and purchasing by expanding utilization management and the use of state Preferred Drug Lists (PDLs) created by an evidence-based evaluation of available therapies. It’s important to include measures to protect access and quality, especially when applied to classes of drugs or medical conditions that have traditionally been excluded from PDLs (such as mental health, HIV/AIDS and cancer).
  • Improve prescriber education by creating an “academic detailing” program that provides prescribers with up-to-date information about the effectiveness of different medications and alternative treatments, serving as an unbiased alternative to pharmaceutical industry promotion.
  • Combat off-label drug promotion and inappropriate prescribing by requiring that physicians inform their Medicaid beneficiary patients whenever the physician prescribes a drug for an unapproved use, and that the patient consents to the treatment.

A Better Path to Savings
These policies — coupled with the consumer-friendly options offered in Sebelius’ letter — offer a clear alternative to cutting low-income children, parents, seniors and people with disabilities off Medicaid; they illustrate why Congress does not need to lift the Maintenance of Effort requirement for states to make their Medicaid programs more efficient.

They also offer clear alternatives to some of the more harmful cost-cutting tools that states already have at their disposal: imposing higher cost-sharing and eliminating or restricting “optional” benefits such as prescription drugs. Those tools just shift costs onto vulnerable beneficiaries, and risk harming their health. And research suggests they result in fewer savings than states might assume: when patients delay or forgo certain services because of cost-sharing or benefit restrictions, their illnesses can worsen and eventually require more expensive care, canceling out some of the state’s savings.

Our letter lays out a better path — one that not only saves money but also can improve the lives of vulnerable Americans. If Governors are serious about fiscal responsibility, they should jump at these opportunities to cut waste and improve the sustainability of the Medicaid program.

-Katherine Howitt, Policy Analyst

Academic detailing and the odds at Agincourt

Thursday, April 22nd, 2010

Today we share a post from Community Catalyst’s prescription drug blog, PostScript.

_______________

We read with interest Merrill Goozner’s blog, “Putting Academic Detailing in Perspective.” See, the Agency for Healthcare Research and Quality recently distributed $30 million of stimulus funds to 9000 locations around the country to get doctors unbiased patient-centered outcome research through academic detailing, also sometimes called prescriber education. (Community Catalyst and the Pew Prescription Project have supported federal and state academic detailing efforts–more here and here.)  Goozner seems to suggest that, while nice,  such grants cannot hope to match “the combined might of the marketing arms of Big Pharma, Big Bio and Big Device.” With a little guess-timation, he says the number of academic detailers that such grants could deploy is a drop in the bucket compared to pharma sales reps: “Do the math,” Goozner writes. “50,000 for the drug industry; 300 for the truth squad. Henry V had better odds at Agincourt.”

Well, sort of. Yes, in numbers, the (shrinking) army of company detailers far outstrips the number of academic detailers currently in the field, or that would be deployed as part of AHRQ grants. But there are other questions of public policy and public health at work here, and it’s worth looking at what those are.

Academic detailing, to refresh, sends trained clinicians such as pharmacists and nurses into the field to talk to doctors. Versed in the body of research on a condition or drug class, the academic detailers talk with doctors about what the science shows to be the safest, most effective treatment out there. They are employed by a nonprofit or a public agency—and therefore not working on a sales commission or motivated by profit to promote one product over another.

Though some doctors may be looking for perks or samples, many say they talk to drug reps because they can’t always find the information they need elsewhere. But it’s more useful for a busy doctor to meet with one academic detailer who knows about all therapies for a given condition and how they’ve faired in trials, than to meet with several commercial detailers, who rarely have clinical backgrounds and are interested, in every case, in talking up one product: theirs.

And there’s the big difference: sales reps are there to sell drugs. Academic detailers are there to talk about what drugs and therapies are out there, and what the science shows works best.

Goozner’s shrug of a post also ignores the bigger picture: Academic detailing isn’t happening in a vacuum. The deployment of prescriber education at local, state and regional levels in the last five years—and now at the federal level—is part of a growing awareness that pharmaceutical marketing has the potential to interfere with safe prescribing and patient care—and a broader effort to make sure it doesn’t.  Medical schools, trade organizations, and a range of medical specialty societies have adopted policies to clarify the relationship between pharmaceutical companies and their members and faculty. Companies have begun to disclose their payments to doctors, and the Physician Payment Sunshine Act passed, establishing a new national transparency standard.

Goozner (and PhRMA President Ken Johnson, in recent comments), seem to suggest that academic detailing is a purely counter-industry tactic, designed to take on—or take down—Big Pharma.  But it isn’t, and to suggest so obscures academic detailing’s real, and very common, mission: to improve clinical care.

There are thousands of investments made daily at local and system-wide levels to improve patient care, and this is one of them. Academic detailing is, at bottom, an effort to improve patient outcomes through rational, evidence-based prescribing. Just as one hospital’s efforts to reduce its infection rates should not be dismissed for not reversing the national trend of hospital-acquired infections, so attempts to get the best science into the hands of doctors who want it should not be dismissed as insignificant or trifling. Good medicine matters, at every level.

–Kate Petersen, PostScript blogger

*if you want to get PostScript in your inbox, subscribe here.